ERBB2 and gastric cancer: This study showed increased overall survival of 13.8 months vs. 11.1 months (p = 0.0046) in those with HER2+ GC treated with trastuzumab in combination with chemotherapy vs. chemotherapy alone, leading trastuzumab to become standard-of-care for advanced HER2+ GC patients.